Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes
February 05 2016 - 9:00AM
iPro2 Professional
CGM Provides Information to Help Physicians Optimize Care for Their
Patients Regardless of Their Diabetes Therapy
MILAN - February 5, 2016 - A
retrospective analysis of the iPro2 Professional CGM from Medtronic
plc (NYSE:MDT), the global leader in medical technology,
demonstrates that patients with type 2 diabetes experience high
rates of glycemic variability, hypoglycemia and hyperglycemia
regardless of whether they manage their diabetes with
diet/exercise, oral medication or insulin. Using this actionable
iPro2 Professional CGM information, physicians can make therapy
adjustments, recommendations and educational decisions for their
patients to help improve glucose control. The results of the
analysis were featured in an oral presentation at the 9th
International Conference on Advanced Technologies & Treatments
for Diabetes (ATTD 2016).
"The use of professional CGM is on the rise. This
retrospective analysis adds to a growing body of literature showing
the benefits of capturing otherwise unrecognized episodes of
hypoglycemia and hyperglycemia as well as identifying excessive
glucose variability," said Robert A. Vigersky, M.D., medical
director for Medtronic Diabetes. "Our data suggests that using
Medtronic's iPro2 Professional CGM provides physicians with
insights to help them optimize therapy recommendations for their
patients with type 2 diabetes, no matter how they are being
treated."
The retrospective analysis of over 80,000 iPro2
Professional CGM procedures in the CareLink® database included
anonymized data from 70,167 patients and 353,520 patient-days in a
diversely treated population of people with type 2 diabetes outside
of the U.S. Results include:
-
Glycemic variability: The
mean glucose was 7.6±2.2 mmol/L for those on diet/exercise, 8.6±2.5
mmol/L for those on oral medication and 9.4±2.6 mmol/L for those on
insulin. Variability metrics were: SD = 1.7, 2.1 and 2.8 mmol/L,
respectively.
-
Hypoglycemia: The daily
incidence rate for hypoglycemia (defined as <3.9 mmol/L) was
0.78±0.74 for diet/exercise, 0.65±0.58 for oral medication and
0.73±0.60 for insulin.
-
Hyperglycemia: All
treatment groups averaged at least one episode of hyperglycemia
(defined as >10.0 mmol/L) per day. The incidence rate was
1.64±1.05 for diet/exercise, 1.8±1.2 for oral medication and
1.93±0.92 for insulin.
The iPro2 Professional CGM system provides
physicians with valuable insights into how their patients' diet,
medication and daily activities affect glucose levels throughout an
entire three-day period. Much like a Holter monitor for
cardiovascular care, iPro2 Professional CGM records a patient's
glucose levels 24 hours a day for up to six days (a total of 1,728
glucose readings) and provides user-friendly reports to the
physician. Physicians may then use these simple reports to make
therapy adjustments, recommendations and educational decisions for
their patients. Medtronic recently introduced enhanced analytical
capability for the iPro2 Professional CGM system. This new
functionality, The CareLink iPro report, named Pattern Snapshot,
helps healthcare professionals quickly uncover hidden hypoglycemic
and hyperglycemic events to guide and educate their patients on
improved glycemic control.
A poster of Pattern Snapshot also presented at
ATTD 2016 highlights the key features of the simple, one-page CGM
report that facilitates interpretation. The report
alleviates some of the physician's burden of data analysis by
providing guidance for changes in diabetes management which is
easily shared with patients.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 85,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Amanda Sheldon
Public Relations
+1-818-576-4826
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#1983963
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024